Interpretation of neutralizing antibodies and myxovirus resitance protein A testing in patients with multiple sclerosis treated with interferon beta

Abstract

Interferon beta (IFN-ß) is one of the first-line treatments in multiple sclerosis. Systematic monitoring of IFN-ß biological effect - regular testing for the presence of neutralizing antibodies and an assessment of mRNA myxovirus resistance protein A levels - should form an integral part of treatment with IFN-ß.

Within the paper, the recommended approach to such monitoring is illustrated by a case report from our clinical practice.

Keywords

• myxovirus
• protein A
• interferon beta